Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25366741 | 0.67 | LMNA (0.36) | LMNAGAAEGFRALDH1A1CYP2C9 | |
| SCHEMBL25366744 | 0.67 | LMNA (0.36) | LMNAGAAEGFRALDH1A1CYP2C9 | |
| SCHEMBL32689845 | 0.67 | KMT2A (0.42) | LMNAGAAGABRA1GABRG2GABRB3 | |
| SCHEMBL24565312 | 0.66 | EGFR (0.49) | LMNAGAAEGFRMEN1POLB | |
| SCHEMBL22323612 | 0.66 | EGFR (0.49) | LMNAGAAEGFRMEN1POLB | |
| SCHEMBL715099 | 0.66 | MMP9 (0.51) | LMNAGAAGABRA1GABRG2GABRB3 | |
| SCHEMBL8676257 | 0.65 | GAA (0.38) | LMNAGAAGABRA1GABRG2GABRB3 | |
| SCHEMBL8678113 | 0.65 | LMNA (0.38) | LMNAGAAGABRA1GABRG2GABRB3 | |
| SCHEMBL8673707 | 0.63 | LMNA (0.36) | LMNAGAAEGFRMEN1POLB | |
| SCHEMBL512776 | 0.62 | GRIN2D (0.39) | LMNAGAAEGFRMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536378-B2 | Prostratin and structural or functional analogs thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-09-17 | — | — | US | disclosed |
| US-20120101283-A1 | Prostratin and Structural or Functional Analogs Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-04-26 | — | — | US | disclosed |
| US-8067632-B2 | Process to produce prostratin and structural or functional analogs thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090187046-A1 | Process to Produce Prostratin and Structural or Functional Analogs Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101283-A1 | Prostratin and Structural or Functional Analogs Thereof | PTGIR, PTGDR, PTGDR2 | LMNA 2709/4885GAA 4465/4885CES2 3422/4885 |
| US-20090187046-A1 | Process to Produce Prostratin and Structural or Functional Analogs Thereof | PTGIR, PTGDR, PTGIS | LMNA 2264/4885GAA 4038/4885CES2 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.